SCHEDULE 13D/A: Bain Capital Entities Increase Stake in Solid Biosciences Following $200 Million Public Offering

Bain Capital-affiliated entities have significantly increased their beneficial ownership in Solid Biosciences Inc. to 9.99% following the company's recent $200 million public offering of common stock and pre-funded warrants.

Summary

• Solid Biosciences Inc. completed an underwritten public offering on February 19, 2025, raising approximately $200 million.
• The offering included 35,739,810 shares of Common Stock at $4.03 per share and pre-funded warrants to purchase 13,888,340 shares of Common Stock at $4.029 per underlying share.
• BCLS II Investco, an entity affiliated with Bain Capital, purchased 1,000,000 shares of Common Stock and a pre-funded warrant for 6,444,170 shares, totaling an aggregate purchase price of $29,993,561.
• The Bain Capital reporting persons collectively beneficially own 9.99% of Solid Biosciences' outstanding Common Stock, representing 7,911,669 shares.
• This beneficial ownership calculation is based on 76,318,810 shares outstanding post-offering and 2,877,087 shares from the pre-funded warrant, adjusted for a 9.99% beneficial ownership blocker.
• The pre-funded warrants are exercisable at $0.001 per share, subject to a beneficial ownership blocker preventing exercise if it would result in ownership exceeding 9.99%.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. The successful completion of a significant capital raise is a positive for the company's financial stability and future operations, and the continued investment by a major life sciences fund indicates investor confidence. The dilution is a negative, but expected with such offerings.

Positives

• Solid Biosciences successfully completed a significant public offering, raising substantial capital for its operations.
• The continued and increased investment by Bain Capital, a prominent life sciences investor, signals confidence in Solid Biosciences' future prospects.
• The capital raise provides the company with financial resources for its ongoing research and development efforts.

Negatives

• The public offering resulted in significant dilution for existing shareholders due to the issuance of new common stock and pre-funded warrants.

Risks

• The 'Beneficial Ownership Blocker' limits the ability of Bain Capital entities to fully exercise their pre-funded warrants if it would cause their collective beneficial ownership to exceed 9.99% of the outstanding Common Stock, potentially restricting their upside from the warrants.

Future Outlook

The document primarily details a completed capital raise and changes in beneficial ownership, rather than providing explicit forward-looking statements or guidance on company performance. However, the successful capital raise implies Solid Biosciences has secured funding to continue its operations and strategic initiatives.

Industry Context

This filing reflects a typical capital raising activity for a biotechnology company, which often rely on equity financing to fund their extensive research and development pipelines. The continued investment by a specialized life sciences fund like Bain Capital underscores ongoing investor interest in the biotech sector, particularly in companies focused on rare diseases like Duchenne Muscular Dystrophy, which Solid Biosciences targets.

Stakeholder Impact

• Shareholders experienced dilution due to the issuance of new shares and warrants in the public offering.
• The company's financial position is strengthened by the capital raise, which can support ongoing operations and strategic initiatives, potentially benefiting long-term shareholders.

Key Dates

Recommendation

Keywords

Solid Biosciences, Bain Capital, Schedule 13D, Common Stock, Pre-Funded Warrants, Public Offering, Equity Investment, Biotechnology, Duchenne Muscular Dystrophy